Exclusive: UK HealthTech Startup Nul Raises €840k in Seed Funding to Help Nullify Alcohol Dependence

Why It Matters

The funding validates digital therapeutics for alcohol use disorder, a largely untapped segment of the health‑tech market, and positions Nul to scale evidence‑based treatment at scale.

Key Takeaways

• €840k seed led by dmg ventures, BYVP
• Platform combines telehealth, naltrexone, Sinclair Method
• 120+ paying users, €344k ARR in months
• Plans UK launch, US expansion, crowdfunding campaign
• Alcohol reduction market remains under‑digitized

Pulse Analysis

Alcohol use disorder remains a significant public‑health challenge, affecting an estimated 283 million people worldwide. Traditional treatment pathways are often fragmented, costly, and carry stigma, limiting access for many sufferers. Digital therapeutics have disrupted adjacent health categories—weight loss, mental health, and chronic disease management—by delivering scalable, data‑driven care. Nul’s entry into this space aligns with a growing investor appetite for solutions that combine pharmaceutical efficacy with telehealth convenience, promising to address a market that has lagged behind in digital innovation.

Nul’s clinical model leverages naltrexone, an opioid antagonist proven to dampen alcohol cravings, alongside the Sinclair Method—a behavioral protocol that conditions reduced consumption through timed medication dosing. By packaging these components into a subscription service that includes virtual consultations, continuous clinical oversight, and structured digital support, Nul creates a seamless patient journey from onboarding to sustained reduction. Early traction—over 120 paying users and an annualised revenue run‑rate near €344 k—demonstrates organic demand and validates the pricing strategy, while partnerships with Blueco Healthcare and Thriva bolster credibility and distribution.

The seed round not only fuels Nul’s UK launch but also signals confidence in the broader health‑tech ecosystem’s ability to tackle alcohol dependence at scale. As regulatory frameworks in the UK and US become more receptive to remote prescribing of FDA‑approved medications, Nul is well‑positioned to expand internationally and capture market share from legacy providers. The upcoming crowdfunding campaign may democratise ownership, fostering a community of advocates while providing additional capital for product development and market penetration. For investors, Nul represents a compelling convergence of clinical science, digital delivery, and a sizable, underserved consumer base poised for disruption.